Clinical Trial: Assessment of the Reactogenicity of ADACEL® (TdcP Vaccine) in Children and Adolescents 7 to 19 Years of Age

Study Status: Completed
Recruit Status: Completed
Study Type: Observational

Official Title:

Brief Summary: To compare the reactogenicity of ADACEL® vaccine given at intervals of 2 to 9 years with the reactogenicity of ADACEL® vaccine given at an interval of 10 or more years following the last previous administration of vaccine containing Diphtheria and Tetanus Toxoids (referred to as TD/Td).

Detailed Summary:
Sponsor: Sanofi Pasteur, a Sanofi Company

Current Primary Outcome: To provide safety information on ADACEL® vaccine given at different time intervals. [ Time Frame: Up to 114 months post-vaccination ]

Original Primary Outcome:

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Sanofi

Dates:
Date Received: September 4, 2007
Date Started: September 2004
Date Completion:
Last Updated: January 10, 2014
Last Verified: January 2014